ClinicalTrials.gg
CompletedNCT00256737Updated Jan 24, 2011

Sopran - Omeprazole Treatment Versus Surgery

A Phase 3 interventional study of Omeprazole in GERD, sponsored by AstraZeneca. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing omeprazole in Gastroesophageal Reflux — 3 open to participants now, 3 under way, none of them phase 3. Omeprazole · Gastroesophageal Reflux.

Enrollment
3rd of 20
219 · median 54
Started
1998
the only one that year
Phase 3
Only one
of the 21
Registered
1st of 21
by date
Lead sponsor
1 of 21
AstraZeneca

Among the 21 studies testing omeprazole in Gastroesophageal Reflux, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 1998, is the only one in phase 3, and was the 1st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

3 of the 21 studies testing omeprazole in Gastroesophageal Reflux are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About omeprazole

Omeprazole: first FDA approval 1989 (PRILOSEC). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing omeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study is to study gastritis, GI symptoms during long term omeprazole treatment

03

Conditions studied

  • GERD

Keywords

  • Maintenance of healed erosive esophagitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous inclusion into Astra study I-635 and willing to continue for another 10 years,

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation; Woman planning pregnancy within 5 years; Suspected or confirmed ; Documented eradication of Helicobacter pylori.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
219 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Determine the safety of omeprazole during long term treatment

Secondary outcomes

  1. To investigate the long term control of reflux symptoms, healing of esophagitis and persistence of post fundoplication symptoms during long term treatment of omeprazole

07

Study locations

13 sites
  • Research Site
    Aalborg, Denmark
  • Research Site
    Glostrup, Denmark
  • Research Site
    Hillerød, Denmark
  • Research Site
    Kolding, Denmark
  • Research Site
    Odense, Denmark
  • Research Site
    Roskilde, Denmark
  • Research Site
    Kuopio, Finland
  • Research Site
    Bergen, Norway
  • Research Site
    Oslo, Norway
  • Research Site
    Trondheim, Norway
  • Research Site
    Göteborg, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Örebro, Sweden
08

References and documents

Publications

  • Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, Langstrom G, Jahreskog M, Eklund S, Lind T, Lundell L. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015 Jun;41(11):1162-74. doi: 10.1111/apt.13194. Epub 2015 Apr 10. PubMed 25858519 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1998, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2005
First posted
Nov 22, 2005
Start
Jan 1998
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00256737
Lead sponsor
AstraZeneca
First posted
Nov 22, 2005
Start date
Jan 1998
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Jan 24, 2011

Study contacts

AstraZeneca GI Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omeprazole

Start the discussion